



IFW 1646

PATENT  
Customer No. 22,852  
Attorney Docket No. 04853.0086-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
OGATA et al. ) Group Art Unit: 1646  
)  
Application No.: 10/019,571 ) Examiner: Ruixiang Li  
)  
Filed: December 31, 2001 ) Confirmation No. 7887  
)  
For: THERAPEUTIC AGENT FOR )  
DISEASES CAUSED BY PTH OR )  
PTHrP )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed foreign and non-patent literature documents are attached.

Applicants also enclose a Supplementary Partial European Search Report and note that several documents have previously been cited.

04/05/2006 HALI11 00000176 10019571

01 FC:1806

180.00 OP

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 4, 2006

By: Amy E. Purcell  
Amy E. Purcell  
Reg. No. 53,492

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>			<b>Complete if Known</b>		
			Application Number	10/019,571	
			PCT Filing Date	July 3, 2000	
			First Named Inventor	OGATA et al.	
			Art Unit	1646	
			Examiner Name	Ruixiang Li	
			Attorney Docket Number	04853.0086-00	
Sheet	1	of	1		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		CA 2 289 910 A1	11-19-1998	TSUNENARI et al.		
		EP 0 341 963 A2	11-15-1989	ROSENBLATT et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		FUNK et al., "Parathyroid Hormone-Related Protein Is Induced During Lethal Endotoxemia and Contributes to Endotoxin-Induced Mortality in Rodents," <i>Molecular Medicine</i> 2(2):204-210 (1996).	
		KOHNO et al., "Synovial Fluids from Patients with Osteoarthritis and Rheumatoid Arthritis Contain High Levels of Parathyroid Hormone-Related Peptide," <i>Journal of Bone and Mineral Research</i> 12(5):847-854 (1997).	
		NAGAO et al., "Central Pressor Effect of Parathyroid Hormone-Related Protein in Conscious Rats," <i>Brain Research</i> 785(1):75-79 (1998).	
		Supplementary Partial European Search Report for EP 00 94 2455, December 23, 2005.	

1077338\_1

Examiner Signature	Date Considered	
--------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.